ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 36845142

Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer.

Zhou K and 3 others. Front Immunol, 2023. Cited by 41 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer. Papers, record 36845142. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36845142

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer.
PubMed
Journal
Front Immunol
PubMed
Year
2023
PubMed
Publication types
Journal Article, Review, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
41
iCite
Relative citation ratio, by iCite
3.51
iCite
Revised in PubMed
2024-09-12
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Zhou KKexun
2Li SShuo
3Zhao YYi
4Cheng KKe

Source PubMed

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Carcinoma, Non-Small-Cell LungMajor topic
Lung NeoplasmsMajor topic
Humans
Immune Checkpoint Inhibitors
Immunotherapy
Drug Resistance
Tumor Microenvironment

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References213

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
128,187,290Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.Cell2017https://conductscience.org/library/papers/28187290PubMed
233,546,704The cancer metabolic reprogramming and immune response.Mol Cancer2021https://conductscience.org/library/papers/33546704PubMed
332,849,616Redefining Tumor-Associated Macrophage Subpopulations and Functions in the Tumor Microenvironment.Front Immunol2020https://conductscience.org/library/papers/32849616PubMed
426,839,260IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance.Trends Immunol2016https://conductscience.org/library/papers/26839260PubMed
534,611,279Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment.Sci Rep2021https://conductscience.org/library/papers/34611279PubMed
633,320,840Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer.J Clin Invest2021https://conductscience.org/library/papers/33320840PubMed
726,321,679Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression.Cell2015https://conductscience.org/library/papers/26321679PubMed
834,093,577The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead.Front Immunol2021https://conductscience.org/library/papers/34093577PubMed
933,393,507Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response.J Clin Invest2021https://conductscience.org/library/papers/33393507PubMed
1035,115,705Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer.Nat Med2022https://conductscience.org/library/papers/35115705PubMed

1 to 10 of 213

See all 213 references

Cited by36

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 41 citations.

PMIDTitleJournalYearIn PapersSource
42,755,977The ALP score: a novel composite index for prognostic risk stratification to chemo-immunotherapy in advanced non-small cell lung cancer.Front Immunol2026https://conductscience.org/library/papers/42755977PubMed
42,626,579A 10-pathway burden score complements tumor mutational burden for outcome stratification in non-small cell lung cancer.Front Med (Lausanne)2026https://conductscience.org/library/papers/42626579PubMed
42,459,668Immune checkpoint inhibitors in dMMR-MSI-H colorectal cancer: rationale, progress and prospects.Front Immunol2026https://conductscience.org/library/papers/42459668PubMed
42,256,528
Multi-omics analysis identifies a major histocompatibility complex class II-associated antigen-presenting cancer-associated fibroblast-like state linked to the nuclear factor erythroid 2-related factor 2-karyopherin subunit beta 1 axis in nonsmall cell lung cancer.
J Cell Commun Signal2026https://conductscience.org/library/papers/42256528PubMed
42,088,497The application and challenges of immune checkpoint inhibitors in lung cancer therapy.Front Immunol2026https://conductscience.org/library/papers/42088497PubMed
42,038,307Protein quality control and antigen presentation in the development of hepatitis B-related hepatocellular carcinoma.Front Pharmacol2026https://conductscience.org/library/papers/42038307PubMed
41,718,747Natural compounds as immune checkpoint inhibitors in melanoma: a systematic review.Naunyn Schmiedebergs Arch Pharmacol2026https://conductscience.org/library/papers/41718747PubMed
41,533,300The MAD2L1-FOXM1 axis negatively regulates CD4⁺ T cell and macrophages infiltration in lung adenocarcinoma.Discov Oncol2026https://conductscience.org/library/papers/41533300PubMed
41,516,132Intratumoral Microbiota in Lung Cancer: Emerging Roles in TME Modulation and Immunotherapy Response.Int J Mol Sci2025https://conductscience.org/library/papers/41516132PubMed
41,369,373Mucosal Melanoma: Mechanisms of Its Etiology, Progression, Resistance and Therapy.Cells2025https://conductscience.org/library/papers/41369373PubMed

1 to 10 of 36

See all 36 cited by

Genes61

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ACAT138PubTator's text mininghttps://conductscience.org/library/genes/38NCBI Gene
AKT1207PubTator's text mininghttps://conductscience.org/library/genes/207NCBI Gene
ALK238PubTator's text mininghttps://conductscience.org/library/genes/238NCBI Gene
APC324PubTator's text mininghttps://conductscience.org/library/genes/324NCBI Gene
ASF1A25,842PubTator's text mininghttps://conductscience.org/library/genes/25842NCBI Gene
B2M567PubTator's text mininghttps://conductscience.org/library/genes/567NCBI Gene
CCR71,236PubTator's text mininghttps://conductscience.org/library/genes/1236NCBI Gene
CD27429,126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
CD28940PubTator's text mininghttps://conductscience.org/library/genes/940NCBI Gene
CD4920PubTator's text mininghttps://conductscience.org/library/genes/920NCBI Gene

1 to 10 of 61

See all 61 genes

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36845142

GET https://conductscience.org/api/papers/v1/36845142/references?page=2

API referenceFor AI assistants